Sarepta Therapeutics
biopharmaceutical company
SRPT Nasdaq
ISIN US8036071004 SEC CIK 873303 LEI 549300IKDPIED8J8IG21
Follow Sarepta Therapeutics
Weekly email: filings, results
Revenue, last quarter
$323.8M
−12.5% vs same quarter last year
Net income
−$28.5M
+43.7% vs same quarter last year
EPS, diluted
−$0.27
+46% vs same quarter last year
Operating cash flow
$60M
+511.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.9B | −$713.4M |
| FY24 | $1.8B | $235.2M |
| FY23 | $1.1B | −$536M |
| FY22 | $843.8M | −$703.5M |
| FY21 | $612.4M | −$418.8M |
| FY20 | $455.9M | −$554.1M |
| FY19 | $380.8M | −$715.1M |
| FY18 | $301M | −$361.9M |
| FY17 | $154.6M | −$50.7M |
| FY16 | $5.4M | −$267.3M |
| FY15 | $1.3M | −$220M |
| FY14 | $9.8M | −$135.8M |
| FY13 | - | −$112M |
| FY12 | - | −$121.3M |
| FY11 | - | −$2.3M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −37.5% | −38.3% |
| FY24 | 12.2% | 13.2% |
| FY23 | −23.4% | −46.8% |
| FY22 | −63.5% | −83.4% |
| FY21 | −75.1% | −68.4% |
| FY20 | −123.8% | −121.6% |
| FY19 | −185.3% | −187.8% |
| FY18 | −114.1% | −120.2% |
| FY17 | −111% | −32.8% |
| FY16 | −4920.3% | −4930.2% |
| FY15 | −17572.5% | −17560.3% |
| FY14 | −1371.2% | −1391.7% |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$307.5M |
| FY24 | −$342.7M |
| FY23 | −$577.1M |
| FY22 | −$356.2M |
| FY21 | −$481.7M |
| FY20 | $25.3M |
| FY19 | −$516.1M |
| FY18 | −$449.8M |
| FY17 | −$244M |
| FY16 | −$251.2M |
| FY15 | −$152.9M |
| FY14 | −$154M |
| FY13 | −$67.1M |
| FY12 | −$29.8M |
| FY11 | −$24.9M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $25M |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Sarepta Therapeutics
- Healthcare median
Show the numbers
| Year | Sarepta Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −38.3% | −30.6% |
| FY24 | 13.2% | −47% |
| FY23 | −46.8% | −58% |
| FY22 | −83.4% | −80.4% |
| FY21 | −68.4% | −71.8% |
| FY20 | −121.6% | −62.2% |
| FY19 | −187.8% | −46.2% |
| FY18 | −120.2% | −49.6% |
| FY17 | −32.8% | −45.9% |
| FY16 | −4930.2% | −36% |
| FY15 | −17560.3% | −37.8% |
| FY14 | −1391.7% | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |